Drug Profile

EZN 4176

Alternative Names: EZN-416; RNA antagonist of the androgen receptor

Latest Information Update: 17 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Santaris Pharma
Developer Enzon Pharmaceuticals; Roche
Class Antineoplastics; Oligonucleotides
Mechanism of Action Androgen receptor antagonists; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Prostate cancer
Discontinued Bone cancer

Most Recent Events

17 Jan 2024 EZN 4176 is still in phase I trial for Prostate cancer in the US and UK (Enzon Pharmaceticals pipeline, January 2024)
16 Oct 2014 Discontinued - Preclinical for Bone cancer in USA (IV)
28 Oct 2013 Enzon Pharmaceuticals terminates its licence for EZN 4176

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com